T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis

Carolina Cruciani, PhD,* Marco Puthenparampil, MD, PhD,* Paula Tomas-Ojer, Ivan Jelcic, PhD, Maria Jose Docampo, PhD, Raquel Planas, PhD, Praveena Manogaran, PhD, Roland Opfer, Carla Wicki, PhD, Markus Reindl, PhD, Ilijas Jelcic, MD, PhD, Andreas Lutterotti, MD, Roland Martin, MD, PhD, and Mireia Sospedra, PhD

Neurol Neuroimmunol Neuroinflamm 2021;8:e1075. doi:10.1212/NXI.0000000000001075

Correspondence
Dr. Sospedra
mireia.sospedraramos@usz.ch

Abstract

Background and Objectives
Encouraged by the enormous progress that the identification of specific autoantigens added to the understanding of neurologic autoimmune diseases, we undertook here an in-depth study of T-cell specificities in the autoimmune disease multiple sclerosis (MS), for which the spectrum of responsible autoantigens is not fully defined yet. The identification of target antigens in MS is crucial for therapeutic strategies aimed to induce antigen-specific tolerance. In addition, knowledge of relevant T-cell targets can improve our understanding of disease heterogeneity, a hallmark of MS that complicates clinical management.

Methods
The proliferative response and interferon gamma (IFN-γ) release of CSF-infiltrating CD4+ T cells from patients with MS against several autoantigens was used to identify patients with different intrathecal T-cell specificities. Fresh CSF-infiltrating and paired circulating lymphocytes in these patients were characterized in depth by ex vivo immunophenotyping and transcriptome analysis of relevant T-cell subsets. Further examination of these patients included CSF markers of inflammation and neurodegeneration and a detailed characterization with respect to demographic, clinical, and MRI features.

Results
By testing CSF-infiltrating CD4+ T cells from 105 patients with MS against seven long-known myelin and five recently described GDP-L-fucose synthase peptides, we identified GDP-L-fucose synthase and myelin oligodendrocyte glycoprotein (35-55) responder patients. Immunophenotyping of CSF and paired blood samples in these patients revealed a significant expansion of an effector memory (CCR7−CD45RA−CD27−Th1 CD4+ cell subset in GDP-L-fucose synthase responders. Subsequent transcriptome analysis of this subset demonstrated expression of Th1 and cytotoxicity-associated genes. Patients with different intrathecal T-cell specificities also differ regarding inflammation- and neurodegeneration-associated biomarkers, imaging findings, expression of HLA class II alleles, and seasonal distribution of the time of the lumbar puncture.

Discussion
Our observations reveal an association between autoantigen reactivity and features of disease heterogeneity that strongly supports an important role of T-cell specificity in MS pathogenesis. These data have the potential to improve patient classification in clinical practice and to guide the development of antigen-specific tolerization strategies.

*These authors contributed equally to this work.
Multiple sclerosis (MS) is considered an immune-mediated demyelinating disease of the CNS.\textsuperscript{1} There is general agreement about the relevance of B cells,\textsuperscript{2} CD8\textsuperscript{+} T cells,\textsuperscript{3,4} and particularly CD4\textsuperscript{+} T cells in MS pathogenesis. However, despite the fact that myelin-specific CD4\textsuperscript{+} T cells can exacerbate MS\textsuperscript{5} and that specific T cells can induce disease in different animal models of MS,\textsuperscript{6,7} there is less consensus about the relevance of CD4\textsuperscript{+} T-cell specificity.

Disease heterogeneity is a hallmark of MS and likely stems from the interplay of a complex genetic background\textsuperscript{8,9} and environmental risk factors.\textsuperscript{10} Although it is well described that disease heterogeneity encompasses composition of tissue lesions, imaging findings, clinical presentation, disease course, and treatment responsiveness, the factors contributing to this heterogeneity, including a putative involvement of T-cell specificity, are not clear. From studies in Experimental Autoimmune Encephalomyelitis (EAE), the most commonly used animal model in MS,\textsuperscript{6,11} it is well known that both the rodent strain, i.e., the genetic background, and the antigen used to induce EAE influence disease course, severity, lesion distribution, and pathologic mechanisms,\textsuperscript{7,12,13} linking T-cell specificity and disease heterogeneity.

The identification of the target antigens in neurologic autoimmune diseases\textsuperscript{14-16} has led to great progress in understanding, diagnosing, and treating these diseases. To better understand and treat MS, researchers have investigated CD4\textsuperscript{+} T-cell specificity for years, albeit with less success than expected. The difficulties in obtaining CNS-infiltrating CD4\textsuperscript{+} T cells, the overall low antigen avidity of self–antigen–reactive T cells, and the limited information about T cell–specific autoantigens in MS have hampered research progress. In addition to the long-known myelin peptides,\textsuperscript{17} few T cell–specific autoantigens have been identified so far. We recently identified GDP-L-fucose synthase (GDP-L-FS)-derived peptides as putative autoantigens in human leukocyte antigen (HLA)-DRB3\textsuperscript{*} patients with MS.\textsuperscript{18}

To evaluate the relevance of CD4\textsuperscript{+} T-cell specificity in MS, we studied their link with features of disease heterogeneity. We identified patients with different CSF-infiltrating CD4\textsuperscript{+} T-cell responses against myelin and GDP-L-FS peptides and characterized them by ex vivo immunophenotyping of CSF and paired blood samples as well as with respect to demographic, clinical, and MRI features.

### Methods

#### Patient Samples

Paired CSF and blood samples were collected from 105 untreated patients with MS, only CSF from 11 control patients (CPs), and 10 patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) negative for anti-AQP4 antibodies and only peripheral blood mononuclear cells (PBMCs) from four healthy donors (HDs) (eTable 1, links.lww.com/NXI/A590). Eighty-four patients with MS (80%) had never been treated, whereas 21 (20%) were previously treated but considered untreated at the time of lumbar puncture (eTable 1, links.lww.com/NXI/A590). Patients and controls were recruited from the NIMS-Neuroimmunology and MS Research Section, Department of Neurology, University Hospital Zurich. MS diagnosis was based on the revised McDonald criteria.\textsuperscript{19}

#### Standard Protocol Approvals, Registrations, and Patient Consents

The Cantonal Ethics Committee of Zurich approved the study procedures (EC-No. 2013-0001). Informed consent was obtained from all patients.

#### CSF and Serum Measures

Albumin quotients and CSF-specific oligoclonal bands were analyzed as previously reported.\textsuperscript{20} Intrathecal Ig synthesis (Ig [loc]) was calculated according to Reiber.\textsuperscript{21}

#### Cell Culture and Stimulation

PBMCs were freshly isolated using Ficoll (Eurobio, Germany) density-gradient centrifugation. CSF-infiltrating CD4\textsuperscript{+} T cells were expanded with phytohaemagglutinin in a single round of stimulation using a previously reported protocol aimed to reduce T cell receptor repertoire bias.\textsuperscript{18} 6 × 10\textsuperscript{5} phytohaemagglutinin-expanded CSF-infiltrating CD4\textsuperscript{+} T cells were seeded in quadruplicate with 2 × 10\textsuperscript{5} irradiated autologous PBMCs as antigen-presenting cells and stimulated with peptides (eTable 2, links.lww.com/NXI/A590) at a final concentration of 10 μM and with a T Cell Activation Kit (anti-CD3, anti-CD28, and anti-CD2 beads) (Miltenyi Biotec) as positive control.

#### Proliferative Responses

We measured proliferation 72 hours after stimulation using 3H-thymidine (Hartmann Analytic, Braunschweig, Germany) as previously reported.\textsuperscript{18} The stimulation index of single wells...
(SI) was calculated as follows: SI = (cpm well with peptide)/(Mean cpm wells without peptide). A well was considered positive if SI ≥2. A patient was considered positive for a peptide if the mean SI of the four wells was ≥2 and at least 3 of the four wells showed a SI ≥2.

Quantification of Cytokines
Release of interferon gamma (IFN-γ) was measured using the ELISA MAX Deluxe Set Human IFN-γ (BioLegend, San Diego, CA) according to the manufacturer’s instructions. A well was considered positive if IFN-γ ≥20 pg/mL, and a patient was considered positive for a peptide if the mean IFN-γ of the four wells was ≥20 pg/mL and at least 3 of the 4 wells were positive.

Cytokines in supernatants and CSF were measured using the Human T Helper Cytokine Panel LEGENDplex bead-based immunoassay (BioLegend) according to the manufacturer’s instructions.

Enzyme-Linked Immunosorbent Assays
The following proteins were quantified using enzyme-linked immunosorbent assay kits: neurofilament light chain (NFL) (Human Diagnostics, Umeå, Sweden); CXCL13/BLC/BCA-1, granzyme A, and granulysin (R&D System, MN); chitinase 3 like 1 (MicroVue, Athens, OH); perforin, granzyme B, and granzyme H (Invitrogen-Thermo Fisher Scientific, MA), were used according to the manufacturer’s instructions.

Statistics
We used GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA) to perform the statistical analysis. We used the unpaired t test to compare two groups of normally distributed variables and U test (Mann-Whitney) for non-normally distributed variables. For the comparison of more than 2 groups of patients, we used the Kruskal-Wallis test for non-normally distributed variables. We used Spearman r to test the linear
correlation between non-normally distributed variables. The significance level was set at $p < 0.05$. Associations between patient specificity, seasonal distribution of lumbar puncture (LP), and HLA were performed using the Fisher exact test with 5% significance.

**Results**

**Identification of GDP-L-FS and Myelin Responders**

Proliferation and IFN-γ release of CSF-infiltrating CD4+ T cells from 105 patients with MS against 5 immunodominant GDP-L-FS18 and 7 myelin peptides31 are shown in eFigure 2A, links.lww.com/NXI/A590. GDP-L-FS peptides induced the highest frequency of positive wells using proliferation as readout and MOG(35-55) peptide using IFN-γ release (Table 1). We also analyzed responses to a viral/bacterial peptide pool cytomegalovirus, Epstein-Barr virus and influenza virus (CEF) (eFigure 2A, links.lww.com/NXI/A590, and Table 1). IFN-γ secretion identified more positive wells than proliferation for myelin and CEF peptides, but comparable results for GDP-L-FS peptides (eFigure 2B, links.lww.com/NXI/A590). Accordingly, the strongest correlation between proliferation and IFN-γ has been found for GDP-L-FS peptides (eFigure 2C, links.lww.com/NXI/A590).

The frequency of patients with positive responses to the different peptides is summarized in Table 1. In 14 patients (13.34%), the main reactivity in proliferation and/or IFN-γ release was against several GDP-L-FS peptides and was classified as GDP-L-FS-responders (Figure 1). Among these, 6 patients (42.8%) showed also positive responses to myelin peptides. The association between GDP-L-FS reactivity and reactivity to myelin peptides was significant ($p \leq 0.0001$, Fisher exact test). Four patients (3.8%) responded only to myelin basic protein (MBP) peptides and were classified as MBP responders, whereas 11 patients (10.4%), responding only against MOG (35-55), were classified as MOG(35-55) responders. Seventy-six patients (72.4%) did not react to any autoantigen and were classified as nonresponders (Figure 1). The response to CEF peptides was comparable in the different groups of patients with the exception of MOG(35-55) responders, in whom it was lower (Figure 1). Because of the low number of MBP responders (<5), this group was not analyzed further.

**Distinct CSF-Infiltrating and Circulating T Cells in GDP-L-FS Responders**

Immunophenotyping of CSF-infiltrating and circulating lymphocytes was performed in a subcohort of patients with MS (eTable 1, links.lww.com/NXI/A590) consisting in GDP-L-FS (n = 7), MOG(35-55) (n = 7), and nonresponder (n = 52) patients (eTable 3, links.lww.com/NXI/A590). Effector memory (EM, CCR7−CD45RA−) CD4+ T cells expressing CD28 but not CD27 (EM CD27−) were significantly more abundant in the CSF of GDP-L-FS responders (Figure 2, A and B, and eFigure 3A, links.lww.com/NXI/A590). Among these EM CD27− cells, only cells with a Th1 (CCR6− CCR4+ CRTTh2+) functional phenotype (EM CD27− Th1), showed significantly higher frequencies (Figure 2B and eFigure 3B, links.lww.com/NXI/A590). Analysis of paired blood samples demonstrated that these cells were also significantly more abundant in frequency and

| Table 1 Percentage of Positive Wells and Patients for Each Peptide Using Proliferation and IFN-γ Release |
|-----------------------------------------------|-----------------------------------------------|
| Positive wells | Positive patients |
| % | % | % | % |
| Proliferation | IFNγ release | Proliferation | IFNγ release |
| GDP-L-FS (51-65) | 5.48 | 7.16 | 3.80 | 5.71 |
| GDP-L-FS (136-150) | 7.14 | 8.35 | 5.71 | 7.62 |
| GDP-L-FS (161-175) | 7.38 | 6.92 | 6.66 | 5.71 |
| GDP-L-FS (246-260) | 6.90 | 8.85 | 4.76 | 8.57 |
| GDP-L-FS (296-310) | 6.43 | 12.65 | 4.76 | 11.42 |
| MBP (13-32) | 0.72 | 4.34 | 0.00 | 1.90 |
| MBP (83-99) | 1.92 | 6.28 | 0.96 | 5.71 |
| MBP (111-129) | 1.20 | 6.75 | 0.96 | 4.76 |
| MBP (146-170) | 0.72 | 3.86 | 0.00 | 2.85 |
| MOG (1-20) | 1.20 | 4.58 | 0.00 | 1.90 |
| MOG (35-55) | 3.61 | 13.49 | 1.92 | 12.38 |
| PLP (139-154) | 1.92 | 3.86 | 0.96 | 3.80 |
| CEF | 23.39 | 38.90 | 22.80 | 35.2 |

Abbreviation: CEF = cytomegalovirus, Epstein-Barr virus and influenza virus; GDP-L-FS = GDP-L-fucose synthase; MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; PLP = Myelin proteolipid protein.
absolute counts in the blood (Figure 2, A and C, and eFigure 3C, links.lww.com/NXI/A590). CSF-infiltrating and circulating CD4+ T cells with a TEMRA (CCR7−CD45RA+) differentiation state and the costimulatory molecules CD28+CD27− and CD28− were also more abundant in GDP-L-FS responders (eFigure 3, A and C, links.lww.com/NXI/A590).

Transcriptional Signatures of EM CD27− CD4+ T Cells in GDP-L-FS Responders

EM CD27− and CD27+ CD4+ T cells were sorted from the peripheral blood of four GDP-L-FS responders (eFigure 4A, links.lww.com/NXI/A590) and the transcriptome analyzed by RNAseq. We identified 265 differentially expressed genes (fold change 1.5, p < 0.001), 119 upregulated and 146 downregulated, in EM CD27− vs EM CD27+ cells (Figure 3A).

The upregulated genes included (1) transcripts linked to cytotoxic CD8+32 and CD4+33 T cells such as ADGRG1 (GPR56), ADGRG5 (GPR114), CCL4, CCL5, CST7, CTSW, CX3CR1, ENC1, FCRL6, FGFR2, GNLy, GZMB, GZMH, MYO6, PRF1, PRSS23, S1PR5, SLAMF7, SPON2, TGFB3, TRGc2, and ZEB2; (2) transcription factors (TFs) important in the development of cytotoxic CD4+ T cells such as Eomesdermin (Eomes)34 and T-bet (encoded by TBX21)35; and (3) other genes associated with Th1 cells such as interferon gamma gene and granzyme A gene (GZMA). In contrast, cytokines, chemokine receptors, and TFs associated with other Th subsets (CCR4, CCR6, IL4R, IL6R, GATA3, and FoxP3) were downregulated in EM CD27− cells.

We also analyzed the same sorted EM subpopulations from four HDs (eFigure 4A, links.lww.com/NXI/A590). The 265 genes that differentiate EM CD27− and CD27+ cells in GDP-L-FS responders did not discriminate EM subpopulations in HDs (Figure 3A). Differential gene expression analysis of EM CD27− cells from GDP-L-FS responders and HDs also identified 145 differentially expressed genes (fold change 1.5, p < 0.001), with 66 upregulated in the GDP-L-FS-responders that include 19 genes linked to cytotoxicity and Th1 T cells and 79 downregulated including genes associated with other T-cell subsets (eFigure 4B, links.lww.com/NXI/A590, and Figure 3A).

The transcription of genes characteristically associated with Th1 cells and cytotoxicity (TBX21, GZMA, EOMES, GNLy, GZMH, and SLAMF7) was overall increased, and transcription of genes associated with other Th subsets (GATA3, CCR4, and CCR6) decreased in EM CD27− cells from GDP-L-FS responders compared with the same cells from HDs and with EM CD27+ cells (Figure 3B).

Characterization of GDP-L-FS- and MOG(35-55)-Specific Responses

The functional phenotype of GDP-L-FS- and MOG(35-55)-specific CD4+ T cells was analyzed in the supernatant of
positive wells stimulated with the cognate antigen (Figure 4A). GDP-L-FS-specific cells released significantly higher amounts of IL-2 than MOG(35-55)-specific cells. This higher IL-2 is most likely involved in the significantly stronger ability of GDP-L-FS-specific cells to proliferate in response to specific peptides, whereas the proliferation to unspecific stimulating beads was comparable in GDP-L-FS- and MOG(35-55)-specific cells (Figure 4B). IFN-γ was the main cytokine released by GDP-L-FS-specific cells indicating a Th1 functional phenotype. MOG(35-55)-specific cells, in addition to IFN-γ, released cytokines associated with other Th subsets (IL-9, IL-6, and IL-10), suggesting a polyfunctional phenotype (Figure 4A). IL-10 also was significantly higher in the CSF of MOG(35-55) responder and Th2-associated cytokines (Figure 4A). Because some of the cytokines released by MOG(35-55)-specific cells have been found elevated in CSF from patients with MOGAD,36 and because both groups of patients share the target antigen, we verified that none of the patients with MS had positive anti-MOG IgG titers in serum or CSF (eTable 4, links.lww.com/NXI/A590) and also analyzed the cytokine profile in the CSF from patients with MOGAD (eTable 1 and
eFigure 5A, links.lww.com/NXI/A590). Although cytokines such as IL-9, IL-22, and IL-6 were high in both groups, the Th2-associated cytokines IL-4 and IL-10 were significantly higher in MOG(35-55) responders (eFigure 5A, links.lww.com/NXI/A590).

Supporting a role of humoral immunity in MOG(35-55) responders, we found significantly higher frequencies of CSF-infiltrating but not circulating naive B cells in these patients (Figure 4C). The amounts in the CSF of CXCL13 were higher in MOG(35-55) responders and chitinase 3 like 1, a general marker of inflammation, in GDP-L-FS responders when compared with CPs (eTable 1, links.lww.com/NXI/A590) (eFigure 5B, links.lww.com/NXI/A590). Both groups of patients showed significantly higher intrathecal IgG synthesis than CP (eFigure 5B, links.lww.com/NXI/A590).

Further CSF analysis of cytotoxic and neurodegenerative markers revealed undetectable amounts of perforin and granzyme B, no significant differences for granulysin, and higher levels of granzyme H, granzyme A, and NfL in GDP-L-FS responders (eFigure 5C, links.lww.com/NXI/A590).

eFigure 5A, links.lww.com/NXI/A590). Although cytokines such as IL-9, IL-22, and IL-6 were high in both groups, the Th2-associated cytokines IL-4 and IL-10 were significantly higher in MOG(35-55) responders (eFigure 5A, links.lww.com/NXI/A590).

Supporting a role of humoral immunity in MOG(35-55) responders, we found significantly higher frequencies of CSF-infiltrating but not circulating naive B cells in these patients (Figure 4C). The amounts in the CSF of CXCL13 were higher in MOG(35-55) responders and chitinase 3 like 1, a general marker of inflammation, in GDP-L-FS responders when compared with CPs (eTable 1, links.lww.com/NXI/A590) (eFigure 5B, links.lww.com/NXI/A590). Both groups of patients showed significantly higher intrathecal IgG synthesis than CP (eFigure 5B, links.lww.com/NXI/A590).

Further CSF analysis of cytotoxic and neurodegenerative markers revealed undetectable amounts of perforin and granzyme B, no significant differences for granulysin, and higher levels of granzyme H, granzyme A, and NfL in GDP-L-FS responders (eFigure 5C, links.lww.com/NXI/A590).

**Association of GDP-L-FS Reactivity and HLA-DRB3*02:02/03:01**

All patients were HLA typed (eTable 5, links.lww.com/NXI/A590). Figure 5A summarizes frequencies of GDP-L-FS, MOG(35-55), and nonresponders expressing the MS-associated DR15 haplotype and DRB3*02:02/03:01 alleles. Based on two previously typed MS cohorts (German cohort [n = 1,270] and Swiss cohort [n = 367]), we expected that 40%–50% of patients with MS express the DR15 haplotype and 30%–40% the DRB3*02:02/03:01 alleles. The frequency of GDP-L-FS responders expressing the DR15 haplotype (21.4%) was lower than expected, whereas those expressing the DRB3*02:02/03:01 alleles (92.8%) were much higher. The association between GDP-L-FS specificity and DRB3*02:02/03:01 alleles was significant (p < 0.0001, Fisher exact test, Figure 5A), confirming our previous results. 

Figure 5B shows CSF-infiltrating CD4+ T-cell responses to GDP-L-FS, myelin, and CEF peptides as well as stimulating...
Figure 4 Characterization of GDP-L-FS- and MOG(35-55)-Specific Responses

(A) Upper graphs, cytokines released by CSF-infiltrating CD4+ T cells from GDP-L-FS and MOG(35-55) responders after stimulation with specific peptides (GDP-L-FS and MOG[35-55]) presented by autologous PBMCs. Four wells were pooled for each patient. Lower graphs, cytokines present in the CSF of GDP-L-FS and MOG(35-55) responders. Cytokines are expressed as pg/ml. (B) Proliferative responses of CSF-infiltrating CD4+ T cells from GDP-L-FS and MOG(35-55) responders after stimulation with the specific peptides presented by autologous PBMCs or anti-CD3, anti-CD28, and anti-CD2 stimulating beads. Proliferative responses are expressed as SI. (C) Frequencies of CSF-infiltrating and blood circulating naive (immunoglobulin D + CD27−) B (CD19+ CD138−) cells in GDP-L-FS and MOG(35-55) responders. Patient color code, GDP-L-FS responders (blue) and MOG(35-55)-responders (red). Each dot in the graphs corresponds to a single patient, and the bars show the mean. The Mann-Whitney test was used to compare GDP-L-FS and MOG(35-55) responders. Statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) is shown. GDP-L-FS = GDP-L-fucose synthase; PBMCs = peripheral blood mononuclear cells.
beads in patients expressing or not DRB3*02:02/03:01 alleles. Only the response to GDP-L-FS peptides, both by proliferation and IFN-γ release, was significantly higher in DRB3*02:02/03:01 patients than in patients expressing other HLA class II alleles.

Demographic and Clinical Features of Patients With Different Specificity

Demographic and clinical characteristics of GDP-L-FS, MOG(35-55), and nonresponder patients did not show significant differences (Table 2). Further characterization revealed a different seasonal distribution regarding the time point when the LP had been performed (Figure 6A), with a significant association between GDP-L-FS specificity and LP during winter/spring months (<0.0001, Fisher exact test).

We also examined markers of compromised blood brain barrier permeability, disease activity, and several MRI parameters (Table 2). Although most of these markers were comparable between GDP-L-FS and MOG(35-55) responders, the semiautomated and blinded analysis of retrospectively collected brain MRI scans from 6 GDP-L-FS and 8 MOG(35-55) responders revealed statistically significant differences. The total number of contrast-enhancing T1 lesions and the total volume of FLAIR T2 lesions (Figure 6B) were significantly higher in GDP-L-FS compared with MOG(35-55) responders.

Discussion

This study represents the most comprehensive analysis of T-cell specificity performed in MS to date because it (1) analyzes CSF-infiltrating CD4+ T cells instead of PBMCs, (2) evaluates the reactivity not only against seven long-known immunodominant/encephalitogenic myelin peptides but also to five recently discovered immunodominant GDP-L-FS peptides, (3) uses as a readout IFN-γ release in addition to proliferation based on the relevant role of Th1 cells in MS, and (4) is performed in a large cohort of 105 patients with MS. Proliferation confirmed a stronger reactivity against GDP-L-FS peptides, whereas IFN-γ release identified MOG(35-55) as the strongest stimulatory peptide. IFN-γ release identified more positive wells than proliferation and should be considered in future studies to avoid underestimating responses. The fact that only 27.6% of patients with MS showed positive responses suggests that we could have missed certain T cells by their too low frequencies or by not testing a broader range of cytokines, target antigens, or epitopes. In
addition, due to the relapsing-remitting nature of inflammation in MS, it is possible that we have missed certain T cells because antigen-specific T cells passage only transiently through the CSF and are not present at the time of the LP. The fact that only 38% of the patients showed T-cell responses against strong viral/bacterial recall antigens supports this notion. Despite these limitations, we identified 14 GDP-L-FS, 4 MBP, and 11 MOG(35-55) responders.

GDP-L-FS responders frequently also recognized myelin peptides. The different sequences of the stimulatory GDP-L-FS and myelin peptides render it unlikely that cross-recognition by single TCCs is behind this association. Instead, a Th1/cytotoxic response that results in the release of new peptides from damaged tissue and the activation of new autoreactive T cells, i.e., epitope spreading, might provide a more plausible explanation. Of interest, ex vivo immunophenotyping

Table 2 Features of Patients With Multiple Sclerosis With Different Specificity

| Demographic and clinical features | All | GDP-L-FS responders | MOG(35-55) responders | Nonresponders |
|----------------------------------|-----|---------------------|----------------------|--------------|
| Number of patients              | 105 | 14                  | 11                   | 76           |
| Female/male ratio               | 1.9 | 1.8                 | 0.8                  | 2.6          |
| Age (y)                         | 34.7 ± 9.1 | 39.1 ± 11.2      | 37.8 ± 11.8          | 34.7 ± 9.2   |
| Age at onset (y)                | 33.2 ± 9.3 | 37.1 ± 10.3       | 35.7 ± 12.3          | 33.1 ± 8.7   |
| Clinical course                 |     |                     |                      |              |
| RIS/CIS (%)                     | 13.3 | 14.3                | 9.1                  | 15.8         |
| RRMS (%)                        | 78.1 | 78.6                | 81.8                 | 76.3         |
| PMS* (%)                        | 8.6 | 7.1                 | 9.1                  | 7.9          |
| Disease duration (mo)           | 28.6 ± 51.9 | 24.3 ± 47.1      | 24.6 ± 31.4          | 30.1 ± 55.9  |
| CSF-specific OCB (%) patients   | 94.2 | 100.0               | 100.0                | 97.4         |

Markers of altered BBB permeability, clinical activity, and brain MRI findings

| GDP-L-FS responders | MOG(35-55) responders | p Value<sup>a</sup> |
|--------------------|----------------------|--------------------|
| CSF cell count (cells/uL) | 7.07 ± 8.87 | 8.00 ± 9.80 | ns |
| BBB damage<sup>b</sup> (% patients) | 35.70 | 36.36 | ns |
| Time since last relapse (d) | 57.09 ± 76.94 | 132.20 ± 220.04 | ns |
| Clinically active (% patients) | 76.92 | 81.81 | ns |
| Brain MRI active (% patients) | 53.84 | 18.18 | ns |
| Brain MRI semiautomatic analysis<sup>c</sup> |     |     |     |
| Volume absolute (mL) |     |     |     |
| Whole brain (mL) | 1,020.58 ± 209.41 | 1,124.69 ± 100.99 | ns |
| Thalamus (mL) | 10.57 ± 1.56 | 11.86 ± 1.03 | ns |
| Gray matter (mL) | 630.05 ± 125.44 | 670.40 ± 48.46 | ns |
| Gd contrast-enhancing T1 lesions (no) | 1.50 ± 1.04 | 0.00 ± 0.00 | 0.001465 |
| FLAIR T2 lesions (no) | 25.83 ± 25.74 | 17.85 ± 22.01 | ns |
| FLAIR T2 lesions total volume (mL) | 4.19 ± 3.17 | 1.25 ± 1.04 | 0.048184 |

Abbreviations: CIS = clinically isolated syndrome; FLAIR = fluid-attenuated inversion recovery; GDP-L-FS = GDP-L-fucose synthase. OCB = oligoclonal band; RIS = radiologic isolated syndrome; RRMS = relapsing remitting MS.  
<sup>a</sup> PMS, progressive MS including primary progressive and secondary progressive MS.  
<sup>b</sup> Blood brain barrier (BBB) damage (Q<sub>ALP-QNORM</sub> > 0).  
<sup>c</sup> Brain MRI semiautomatic analysis was performed in 6 GDP-L-FS and 8 MOG(35-55) responder patients from which brain MRIs at the time of LP were available.  
<sup>d</sup>p value, for the comparison of two groups of patients, we used the unpaired t test for normally distributed variables and the U test (Mann-Whitney) for non-normally distributed variables.  
Bold numbers indicated statistically significant differences.
demonstrated that EM CD27− Th1 CD4+ were significantly more abundant in the CSF and also peripheral blood of GDP-L-FS-responders and that these cells in the blood expressed Th1- and cytotoxicity-associated genes.33 Whether this T-cell subset is enriched in GDP-L-FS-specific cells is still unknown and requires further investigation. Remarkably, high dimensional single cell analysis of CD4+ T cells from patients with rheumatoid arthritis (RA) identified an equivalent expanded EM CD27− CD4+ T-cell subset with a very similar transcriptome profile42 supporting a broader role of this cell subset in autoimmunity. Furthermore, both GDP-L-FS responders and patients with RA also have higher frequencies of TEMRA CD28+ CD27− and CD28- cells that have been associated with damage and clinical progression in RA.43 Cytokine analysis showed a relevant role of Th1 responses in GDP-L-FS responders and Th2 in MOG(35-55) responders. GDP-L-FS- and MOG(35-55)-specific cells did not release IL-17, a cytokine reported to be relevant in MS.44 Th17 and Th1* cells in patients with MS most likely have specificities that have not been included in this study. The higher intrathecal amounts of Th2 cytokines in MOG(35-55) responders suggest a role of humoral immunity in these patients. Accordingly, they showed higher frequencies of CSF-infiltrating naive B cells and higher CXCL13 levels.37 These patients also showed higher intrathecal amounts of IL-10 that might regulate Th2 responses as it has been reported in allergy.45 GDP-L-FS-specific responses were associated with DRB3*02:02/03:01 alleles, confirming previous results,18 and were significantly more frequent in CSF samples obtained during winter and spring. Seasonality of infections as triggers of autoreactive T cells might underly this annual distribution, but gut microbiota dysbiosis due to seasonal changes in diet46 and vitamin D47 should also be considered because CSF-infiltrating CD4+ T cells from GDP-L-FS responders cross-recognized homologous bacterial peptides.18 Finally, GDP-L-FS and MOG(35-55) responders also differed regarding MRI findings. It is remarkable that, despite the low number of patients from whom brain MRI scans were available at the time of LP, GDP-L-FS responders showed significantly higher numbers of contrast-enhancing T1 lesions and higher volumes of FLAIR T2 lesions, indicating higher inflammation and more extensive demyelination accordingly with more damaging immune responses.

In summary, our results reveal, an association between T-cell specificity and features of disease heterogeneity in a T cell

Figure 6 Characterization of GDP-L-FS and MOG(35-55) Responder Patients

(A) Monthly distribution of LPs and frequency of samples obtained in winter/spring and summer/autumn in GDP-L-FS, MOG(35-55), and nonresponders. Red shadows show months with higher differences. Number of patients responding or not to GDP-L-FS in which LP was obtained in winter/spring (Y, yes) or not (N, not) and p values for Fisher exact tests are shown. (B) Number of total contrast-enhancing T1 lesions and total volume of flair T2 lesions (expressed in mL) in GDP-L-FS- and MOG(35-55) responders. Each dot in the graphs corresponds to a single patient, and the bars show the mean. We used t test for normally distributed variables to compare two groups of patients. Statistical significance (**p < 0.01) is shown. GDP-L-FS = GDP-l-fucose synthase.
mediated autoimmune disease. A parallel association between disease severity and autoantibodies against citrullinated peptides is well described in patients with RA.\(^ {48-50}\) The utility of this long-known association in the clinical management of patients with RA indicates the potential of our findings to improve clinical care and treatment decisions. In addition, our results might have important implications for personalized treatment approaches aiming at antigen-specific tolerance.

**Study Funding**

This work has been funded by European Research Council Advanced Grant (340733) (R.M.), Clinical Research Priority Program MS (CRPPMS) and (CRPP) PrecisionMS of the University Zurich (R.M., M.S., and A.L.), Clinical, Swiss National Science Foundation (Sinergia UnmetMS) (R.M. and M.S.) and the Swiss MS Society (R.M.).

**Disclosure**

All authors except R.M. and M.S. declare that they have no competing financial interests in the context of this work. R.M. and M.S. hold a patent on immunodominant proteins and fragments in autoimmune diseases (EP18180326.3; 2018). Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation April 26, 2021. Accepted in final form July 15, 2021.

---

**Appendix Authors**

| Name                        | Location                                                                 | Contribution                                                                 |
|-----------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Carolina Cruciani, PhD      | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Major role in the acquisition of data and analysis or interpretation of data |
| Marco Puthenparampil, MD, PhD | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland; Department of Neuroscience DNS, University-Hospital of Padova, Padova, Italy | Major role in the acquisition of data and analysis or interpretation of data |
| Paula Tomas-Ojer            | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Major role in the acquisition of data                                         |
| Ivan Jelcic, PhD            | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Major role in the acquisition of data                                         |

**Appendix (continued)**

| Name                        | Location                                                                 | Contribution                                                                 |
|-----------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Maria Jose Docampo, PhD     | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Major role in the acquisition of data                                         |
| Raquel Planas, PhD          | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Major role in the acquisition of data                                         |
| Praveena Manogaran, PhD     | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Analysis or interpretation of data                                          |
| Roland Opfer                | Jung Diagnostics GmbH, H.I.P. Health Innovation Port, Hamburg, Germany    | Analysis or interpretation of data                                          |
| Carla Wicki, PhD            | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Analysis or interpretation of data                                          |
| Markus Reindl, PhD          | Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria | Major role in the acquisition of data                                         |
| Iljias Jelcic, MD, PhD       | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Analysis or interpretation of data                                          |
| Andreas Lutterotti, MD      | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Analysis or interpretation of data                                          |
| Roland Martin, MD, PhD      | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Drafting/revision of the manuscript for content, including medical writing for content, and study concept or design |
| Mireia Sospedra, PhD        | Neuroimmunology and MS Research (NIMS), Department of Neurology, University Hospital and University Zurich, Zürich, Switzerland | Drafting/revision of the manuscript for content; study concept or design; and analysis or interpretation of data |

**References**

1. Sospedra M, Martin R. Immunology of multiple sclerosis. *Annu Rev Immunol*. 2005;23(1):683-747.
2. Sospedra M. B cells in multiple sclerosis. *Carr Opin Neurol*. 2018;31(3):256-262.
3. Fogdell-Hahn A, Liggers A, Groenning M, Hillert J, Oferup O. Multiple sclerosis: a modifying influence of HLA class II associated autoimmune disease. *Tissue Antigens*. 2000;55(2):140-148.
4. Friese MA, Jakobsen KB, Friis L, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. *Nat Med.* 2008;14(11): 1227-1235.

5. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. *Nat Med.* 2000;6(10):1167-1175.

6. Miller SD, Karpus WJ. Experimental autoimmune encephalomyelitis in the mouse. *Curr Protoc Immunol.* 2007; Chapter 15: Unit 15.1.

7. Weisset R. Actively induced experimental autoimmune encephalomyelitis in rats. *Methods Mol Biol.* 2016;1304:161-169.

8. International Multiple Sclerosis Genetics Consortium, Beecham AH, Patapouski NA, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat Genet.* 2013;45(11):1353-1360.

9. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science.* 2019; 365(6460):eaav7188.

10. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nat Rev Neurol.* 2017;13(1):25-36.

11. Bjelobaba I, Begovic-Kupresanin V, Pekovic S, Lavrnja I. Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis. *J Neurosci Res.* 2018; 96(6):1021-1042.

12. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAEE) using an encephalitogenic epitope of proteolipid protein. *J Immunol.* 1992; 149(3):854-860.

13. Manogaran P, Samardzija M, Schad AN, et al. Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis. *Acta Neuropathol Commun.* 2019;7(1):116.

14. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. *Neurology.* 2018;91(3):1227-1235.

15. Dalmau J, Arranz J, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. *J Neurovirol.* 2019;18(1):1045-1057.

16. Hohlfeld R, Dormarik K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. *J Neurovirol.* 2016;16(5):198-209.

17. Planas R, Santos R, Tomas-Ojer P, et al. GDP-fucose synthase is a CD4+ T cell-active and adoptive relapsing experimental autoimmune encephalomyelitis (EAEE) using an encephalitogenic epitope of proteolipid protein. *J Immunol.* 1992;149(3):854-860.

18. Dalmau J, Aranguren C, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. *J Neurovirol.* 2019;18(1):1045-1057.

19. Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. *Mult Scler.* 2009;15(12):1486-1490.

20. Brodie T, Rothauer K, Sospedra M. OMIM:033: a comprehensive single step staining protocol for human T- and B-cells in flow cytometry. *J Immunol.* 2016;196(7):629-632.

21. Jelic I, Al Nimer F, Wang J, et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. *Cell.* 2018;175(1):e2-130.e23.

22. Bolger AM, Lohse M, Usadel B. Trimmomatic: a high-performance variant of the atlases. *Ann Rheum Dis.* 2009;68(5):736-737.

23. Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. *Neurol Neuroimmunol Neuroinflamm.* 2020;7(2):17.

24. Krüger J, Opfer R, Gessert N, et al. Fully automated longitudinal segmentation of new or enlarged multiple sclerosis lesions using 3D convolutional neural networks. *Neuroimage Clin.* 2020;28:102445.

25. Schippings L, Ostwalde AC, Suppa P, et al. Global and regional annual brain volume loss rates in physiological aging. *J Neurol.* 2017;264(3):520-528.

26. Robinson MJ, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010; 26(1):139-140.

27. Robinson MJ, McCarthy DJ, Smyth GK. edger: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010; 26(1):139-140.

28. Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. *Neurol Neuroimmunol Neuroinflamm.* 2020;7(2):17.

29. Hidalgo LG, Einecke G, Allanach K, Halloran PF. The transcriptional signature of human cytotoxic T cells: similarities and disparities among allstimulated CD4+ T cells in multiple sclerosis. *J Immunol.* 2004;172(6):3893-3904.

30. Patil VS, Madrigal A, Schmiedel BJ, et al. Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. *Sci Immunol.* 2018; 3(19):eaan8664.

31. Pearce EL, Mullen AC, Martins GA, et al. Control of effector CD8+ T cell function by the transcription factor eomesodermin. *Science.* 2003;302(5647):1041-1043.

32. Eshima K, Chuha S, Suzuki H, et al. Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4+ T cells cytotoxic by activating both perforin- and FasL-pathways. *Immunol Lett.* 2012;144(1-2):7-15.

33. Patil VS, Madrigal A, Schmiedel BJ, et al. Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. *Sci Immunol.* 2018; 3(19):eaan8664.
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis
Carolina Cruciani, Marco Puthenparampil, Paula Tomas-Ojer, et al.

Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000001075

This information is current as of September 17, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/6/e1075.full.html

References
This article cites 49 articles, 13 of which you can access for free at:
http://nn.neurology.org/content/8/6/e1075.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Immunology
http://nn.neurology.org/cgi/collection/all_immunology
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.